The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst)
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai (Inst)
 
Min Ren
Employment - Eisai
 
Mahadi Ali Baig
Employment - Eisai
 
Mayer N. Fishman
Consulting or Advisory Role - Alkermes; Eisai
Speakers' Bureau - GlaxoSmithKline; Pfizer
Research Funding - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer; Prometheus
Patents, Royalties, Other Intellectual Property - N/A
Other Relationship - M2Gen; NCCN